COMMUNIQUÉS West-GlobeNewswire

AxoGen to Host Second Annual Analyst and Investor Day on November 20, 2017
07/11/2017
ALACHUA, Fla., Nov. 07, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, today announced that it [...]
Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results
07/11/2017
BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial [...]
Aclaris Therapeutics Reports Third Quarter 2017 Financial Results
07/11/2017
Management to Host Conference Call at 8:00 AM ET today
Targovax ASA: Notice of Extraordinary General Meeting
07/11/2017
An Extraordinary General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 30 November 2017 at 13:00 CET. Please find the notice including agenda for the Extraordinary General Meeting and [...]
Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
07/11/2017
Top-line data from the study now expected in mid-2018 LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on [...]
Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017
07/11/2017
Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or [...]
Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation
07/11/2017
ORION CORPORATION PRESS RELEASE 7 NOVEMBER 2017 at 8.30 EET Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation Professor Heikki Joensuu, M.D., Ph.D., has [...]
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
07/11/2017
Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx ® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced mobility and irreversible joint [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
07/11/2017
REGULATED INFORMATION GHENT, Belgium, 7 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
07/11/2017
REGULATED INFORMATION GHENT, Belgium, 7 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
CORRECTION OF PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
07/11/2017
REGULATED INFORMATION GHENT, Belgium, 7 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] announced on 3 November 2017, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication [...]
Todd Bazemore Steps Down from Role as Chief Operating Officer of Santhera's US Subsidiary
06/11/2017
Liestal, Switzerland, November 6, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that Todd Bazemore resigns his role as Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc. and member of executive [...]
VALNEVA : Déclaration d'actions et de droits de vote octobre 2017
06/11/2017
VALNEVA Déclaration d'actions et de droits de vote - OCTOBRE 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon - Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2017
06/11/2017
Nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France [...]
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2017
06/11/2017
Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Le MABp1 de XBiotech fera l'objet d'une présentation orale lors des séances scientifiques de l'American Heart Association
06/11/2017
Présentation pour discuter des nouveaux résultats sur MABp1 dans la prévention de la thrombose coronaire AUSTIN, Texas, le 3 novembre 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui que la [...]
Ossur Hf : Transactions in relation to share buyback program
06/11/2017
Announcement from Össur hf. No. 80/2017 Reykjavík, 6 November 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Acarix AB to seek new CEO
06/11/2017
Press release Malmö, November 6, 2017 Acarix AB to seek new CEO Acarix AB (publ) ("Acarix") announced today that CEO Søren Rysholt Christiansen has resigned on 6 Nov. 2017, with the effect to leave the company at the [...]
Adaptimmune marks Official Opening of U.K. Headquarters
06/11/2017
Flagship Facility is new Base for U.K. Research and Development Operations PHILADELPHIA and OXFORD, U.K., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat [...]

Pages